Skip to main content
Loading

Pinetree Therapeutics

October 18, 2023
Franciscan C
Oncology
Pinetree Therapeutics is a biotechnology developing novel medicines to combat drug resistance in oncology and beyond. Pinetree's platform technology AbReptorâ„¢ is a first and best-in-class, transformative and modular bi-specific and multi-specific antibody platform designed to target-degrade membrane-bound and extracellular proteins. AbReptorâ„¢ works by co-engaging a surface-receptor or extracellular protein of interest together with another proprietary receptor target. Since its founding in 2019 Pinetree's R&D efforts have brought about several compelling pre-clinical programs including lead asset PTX-299, a bispecific antibody candidate that holds promise as a first and best-in-class treatment for EGFR-driven cancers and is currently in IND-enabling toxicology studies.
Speakers
Ho-Juhn Song - Pinetree Therapeutics